

23 April 2025

Request under Freedom of Information Act 2000

Thank you for your request for information which we received on Thursday 17 April 2025. I am pleased to confirm the following.

Q1. Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which.

99

Q2. Of the multiple myeloma patients treated over the past 6 months, how many were treated with the following:

- Any other systemic anti-cancer therapy- Bendamustine Thalidomide - 1
- Belantamab Mafodotin [Blenrep] - 0
- Belantamab Mafodotin [Blenrep] with bortezomib and dexamethasone - 0
- Belantamab Mafodotin [Blenrep] with pomalidomide and dexamethasone - 0
- Bortezomib [Velcade] monotherapy or with dexamethasone - 0
- Bortezomib [Velcade], Melphalan/Cyclophosphamide and prednisolone/dexamethasone (VMp or VCd) - 12
- Bortezomib, thalidomide and dexamethasone [VTD] - 3
- Carfilzomib [Kyprolis] and dexamethasone - 0
- Carfilzomib [Kyprolis], Lenalidomide [Revlimid] and dexamethasone - 3
- Daratumumab [Darzalex] with Lenalidomide [Revlimid] and dexamethasone - 7
- Daratumumab [Darzalex] monotherapy - 18
- Daratumumab [Darzalex], Bortezomib [Velcade] and dexamethasone (known as DVd or DBd) - 4
- Daratumumab [Darzalex], Bortezomib [Velcade], thalidomide and dexamethasone (known as Dara-VTd) - 9
- Elranatamab - 6
- Idecabtagene vicleucel [Abecma] - 0
- Isatuximab [Sarclisa], Pomalidomide [Imnovid] and dexamethasone (known as IsaPd) - 12
- Ixazomib [Ninlaro], Lenalidomide [Revlimid] and dexamethasone (known as IRd) - 10
- Lenalidomide [Revlimid] and dexamethasone - 28
- Lenalidomide [Revlimid] monotherapy - 3

- Panobinostat in combination with Bortezomib and Dezamethasone - 0
- Pomalidomide [Imnovid] and dexamethasone - 0
- Selinexor and dexamethasone - 0
- Selinexor, Bortezomiv [Velcade] and dexamethasone - 0
- Talquetamab - 0
- Teclistamab [Tecvayli] - 0

Please be advised that this information is provided in accordance with the Freedom of Information Act 2000 and is for your personal use. Any re-use of this information will be subject to copyright and the Re-Use of Public Sector Information Regulations (1st July 05) and authorisation from Milton Keynes Hospital NHS Foundation Trust will be required. In the event of any re-use, the information must be reproduced accurately and not used in a misleading manner.

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD. If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely

Information Governance Administrator
For and on behalf of Milton Keynes Hospital NHS Foundation Trust

Any re-use of this information will be subject to the
'Re-use of Public Sector Information Regulations' and best practice.